Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q4 owing to continued rise in Catalyst and premium hematology placements.
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.